Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3994474 | 0.98 | CHRM1 (0.39) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL4983975 | 0.83 | CHRM1 (0.43) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL3991897 | 0.81 | CPB2 (0.42) | ADRA1ATDP1CA2CPB2LMNA | |
| SCHEMBL3992467 | 0.80 | SLC1A2 (0.40) | TDP1CA2MAPK1SLC1A2SLC1A1 | |
| SCHEMBL12391770 | 0.79 | CPB2 (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL8847224 | 0.77 | GRIK1 (0.43) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL18762598 | 0.76 | SLC1A2 (0.44) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL18775003 | 0.76 | SLC1A2 (0.44) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL18775000 | 0.76 | SLC1A2 (0.44) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL1561601 | 0.74 | LMNA (0.37) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1614675-A2 | Amino acids with affinity for the alpha-2-delta protein | Warner-Lambert Company LLC (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | BARTA NANCY SUE | 2005-12-08 | — | — | US | claimed |
| EP-1492761-B1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER LAMBERT CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7517909-B2 | Amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE | 2006-11-02 | — | — | US | disclosed |
| US-7112610-B2 | Methods for using amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY S | 2006-07-13 | — | — | US | disclosed |
| EP-1670452-A2 | METHOD OF USE OF AMINOACIDS HAVING AFFINITY FOR THE A2D PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7064147-B2 | Amino acids with affinity for the α-2-delta-protein | WARNER-LAMBERT COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1614675-A2 | Amino acids with affinity for the alpha-2-delta protein | Warner-Lambert Company LLC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | BARTA NANCY SUE | 2005-12-08 | — | — | US | disclosed |
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005030184-A2 | THERAPEUTIC BETA AMINOACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1492761-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | CHRM1 2872/4885AKR1A1 4215/4885CHRM3 2717/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | CHRM1 2860/4885AKR1A1 4393/4885CHRM3 2651/4885 |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | CHRM1 2808/4885AKR1A1 4148/4885CHRM3 3193/4885 |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, SCN1A | CHRM1 2110/4885AKR1A1 4114/4885CHRM3 2401/4885 |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | CHRM1 2872/4885AKR1A1 4215/4885CHRM3 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.